CriticalAntiviral for systemic use, HIV-1 protease inhibitor; used only with a pharmacokinetic booster (ritonavir or cobicistat)×Antianginal – late sodium current inhibitor
Updated · Methodology
Mechanism
The liver and gut break down ranolazine mainly through the enzyme CYP3A4 and to a lesser extent through CYP2D6. Ranolazine is also a substrate of the transporter P-glycoprotein, and inhibitors of CYP3A4 and P-glycoprotein raise its levels (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA; ranolazine label, US Food and Drug Administration, FDA). Darunavir is taken only with a booster, ritonavir or cobicistat, and this regimen inhibits CYP3A, CYP2D6 and P-glycoprotein (darunavir SmPCs, EMA, and darunavir labels, FDA). No study has tested the pair, but according to the darunavir SmPCs, ranolazine levels are likely to rise (darunavir SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, and EMA). For comparison, the strong CYP3A4 inhibitor ketoconazole increased the area under the concentration-time curve (AUC) of ranolazine 3.0- to 3.9-fold (ranolazine SmPC, EMA). As ranolazine levels rise, so does the risk of dose-dependent adverse effects, such as nausea and dizziness, and of prolongation of the corrected QT interval (QTc) (ranolazine SmPC, EMA).
Symptoms
Dizziness, nausea and vomiting become more frequent as the ranolazine dose rises (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). Ranolazine prolongs the corrected QT interval (QTc) in a dose-dependent way. The prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG) (ranolazine SmPC, EMA). Ranolazine overdose has caused low blood pressure, QT prolongation, slow heart rate, muscle jerks, severe tremor, unsteady gait, dizziness, nausea, vomiting, speech difficulty and hallucinations. Extreme overdose has been fatal (ranolazine label, US Food and Drug Administration, FDA).
Management
The combination is contraindicated. Ranolazine is on the contraindication list of darunavir boosted with either ritonavir or cobicistat, including the fixed-dose darunavir/cobicistat tablet (darunavir and darunavir/cobicistat summaries of product characteristics, SmPCs, European Medicines Agency, EMA; darunavir and darunavir/cobicistat labels, US Food and Drug Administration, FDA). The ranolazine SmPC contraindicates strong CYP3A4 inhibitors and names human immunodeficiency virus (HIV) protease inhibitors among them (ranolazine SmPC, EMA). The US ranolazine label also names ritonavir among these inhibitors (ranolazine FDA label). Ranolazine is an add-on to beta-blockers or calcium antagonists when they are not enough or not tolerated (ranolazine SmPC, EMA). Darunavir can be combined with calcium antagonists and beta-blockers under clinical monitoring. For carvedilol, metoprolol and timolol, which are cleared by CYP2D6, consider a lower dose (darunavir SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Before and during darunavir treatment, review interactions in the full prescribing information (darunavir/cobicistat FDA label). If the patient has nevertheless taken ranolazine with darunavir and shows signs of ranolazine overdose, monitor closely and give symptomatic and supportive treatment. Continuous electrocardiogram (ECG) monitoring may be needed (ranolazine SmPC, EMA, and ranolazine FDA label). Haemodialysis is unlikely to remove ranolazine completely, because about 62% of it is bound to plasma proteins (ranolazine SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ranolazine extended-release tablets (Zydus Lifesciences) – prescribing information (2026)– FDA label, Zydus Lifesciences, DailyMed setid d74f3dea-7357-4e9a-be9a-2f498a44108a, version 5, 09/2026, sections 2.2, 4, 5.1, 7.1 and 7.2
- FDA: Prezista (darunavir) prescribing information (2025)– FDA, DailyMed, setid 814301f9-c990-46a5-b481-2879a521a16f, SPL 08/2025 (Revised 03/2023), sections 4 and 7 (Table 10)
- EMA: Ficha técnica: Darunavir (Prezista, EU/1/06/380), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 106380007 (EU/1/06/380), secciones 4.3 y 4.5, consultado 10/2026
- EMA: Ficha técnica: Ranolazina (EU/1/08/462), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 08462001 (EU/1/08/462), secciones 4.3, 4.5 y 4.9, consultado 10/2026
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.5 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Darunavir (Darunavir Aurovitas, nº registro 84835), sección 4.5 (2023)– AEMPS, CIMA, nº registro 84835, revisión 09/2023, secciones 4.3 y 4.5
- FDA: PREZCOBIX (darunavir and cobicistat) prescribing information (2026)– FDA, DailyMed setid 9c38fdb6-d0ba-4f16-a0e3-85d9ec334d9f (Janssen Products), revisión 02/2026 (versión 29), secciones 4, 6.2, 7.1 y 7.3